NYSEAMERICAN:BTX - BioTime Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.9998 -0.07 (-6.54 %)
(As of 01/21/2019 03:04 PM ET)
Previous Close$1.07
Today's Range$0.9770 - $1.09
52-Week Range$0.66 - $3.16
Volume808,819 shs
Average Volume370,831 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy. It also develops Premvia, a HyStem hydrogel formulation for use in the treatment of age-related facial lipoatrophy, as well as for the management of wounds, including partial and full-thickness wounds, ulcers, tunneled/undermined wounds, surgical wounds, and burns; and ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis. In addition, the company through its subsidiary, AgeX Therapeutics, Inc., develops AGEX-BAT1 that consists of pluripotent stem cell-derived brown adipocytes for the treatment of type 2 diabetes; AGEX-VASC1, which consists of vascular progenitors targeting cardiac ischemia; and induced tissue regeneration, a systemic therapy for inducing the scar less regeneration of tissues. Further, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions. BioTime, Inc. was founded in 1990 and is based in Alameda, California.

Receive BTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNYSEAMERICAN:BTX
Previous SymbolNYSEMKT:BTX
CUSIP09066L10
Phone+1-510-5213390

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees92
OptionableOptionable

BioTime (NYSEAMERICAN:BTX) Frequently Asked Questions

What is BioTime's stock symbol?

BioTime trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX."

How were BioTime's earnings last quarter?

BioTime, Inc. (NYSEAMERICAN:BTX) issued its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.01. The biotechnology company had revenue of $0.98 million for the quarter, compared to the consensus estimate of $0.75 million. View BioTime's Earnings History.

When is BioTime's next earnings date?

BioTime is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for BioTime.

What price target have analysts set for BTX?

3 equities research analysts have issued 1 year target prices for BioTime's shares. Their forecasts range from $3.50 to $8.00. On average, they expect BioTime's share price to reach $5.00 in the next year. This suggests a possible upside of 400.1% from the stock's current price. View Analyst Price Targets for BioTime.

What is the consensus analysts' recommendation for BioTime?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTime in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTime.

Has BioTime been receiving favorable news coverage?

News stories about BTX stock have trended very positive on Monday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BioTime earned a coverage optimism score of 3.2 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Are investors shorting BioTime?

BioTime saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 11,732,847 shares, a decline of 18.1% from the December 14th total of 14,320,748 shares. Based on an average trading volume of 1,152,378 shares, the short-interest ratio is presently 10.2 days. Approximately 9.3% of the company's shares are sold short. View BioTime's Current Options Chain.

Who are some of BioTime's key competitors?

Who are BioTime's key executives?

BioTime's management team includes the folowing people:
  • Mr. Russell L. Skibsted, Chief Financial Officer (Age 60)
  • Dr. Stephana E. Patton, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 48)
  • Mr. William Annett, Pres & CEO of OncoCyte Corp. (Age 65)
  • Mr. Brian M. Culley, CEO , Pres & Director (Age 48)
  • Mr. David Nakasone, Director of Investor Relations

Who are BioTime's major shareholders?

BioTime's stock is owned by many different of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.03%). Company insiders that own BioTime stock include Aditya P Mohanty, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Institutional Ownership Trends for BioTime.

Which institutional investors are buying BioTime stock?

BTX stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought BioTime stock in the last two years include Aditya P Mohanty, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Insider Buying and Selling for BioTime.

How do I buy shares of BioTime?

Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioTime's stock price today?

One share of BTX stock can currently be purchased for approximately $0.9998.

What is BioTime's official website?

The official website for BioTime is http://www.biotimeinc.com/.

How can I contact BioTime?

BioTime's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-5213390.


MarketBeat Community Rating for BioTime (NYSEAMERICAN BTX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  166 (Vote Underperform)
Total Votes:  330
MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote "Outperform" if you believe BTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel